Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia—A Multicenter Report by the Polish Lymphoma Research Group

Joanna Drozd‐Sokołowska, Anna Waszczuk‐Gajda, Magdalena Witkowska, Elżbieta Sienkiewicz, Anna Kopińska, Agnieszka Kołkowska‐Leśniak, Joanna Barankiewicz, Monika Długosz‐Danecka, Piotr Smolewski, Grzegorz Helbig, Ewa Lech‐Marańda, Wojciech Jurczak, Przemysław Biecek, Sebastian Giebel, W Wiktor-Jędrzejczak, Grzegorz BasakJournal of Clinical Medicine 2022 · DOI

TL;DR

Bing-Neel Syndrome (BNS), a rare central nervous system complication of Waldenström Macroglobulinemia (WM), is poorly understood due to its scarcity. This multicenter Polish study analyzed 11 BNS patients, revealing a challenging diagnosis, diverse clinical presentations, and a poor prognosis, highlighting the need for increased physician awareness and improved treatment strategies.

What Problem Does This Paper Address?

Waldenström Macroglobulinemia (WM) is a rare B-cell lymphoma. A particularly rare and severe complication of WM is Bing-Neel Syndrome (BNS), which involves the central nervous system (CNS) and sometimes the peripheral nervous system. BNS is challenging to diagnose because its symptoms can be varied and mimic other WM complications, and it can occur at any stage of WM, even in previously undiagnosed patients. Due to its rarity, there's a significant lack of data on BNS patients, including their clinical characteristics, treatment effectiveness, and prognosis. This scarcity makes it difficult for clinicians to effectively manage BNS. This paper aims to address this knowledge gap by presenting a multicenter retrospective analysis of BNS cases from Poland, contributing much-needed data to the literature.

Methods

This study employed a retrospective, multicenter design, analyzing data from patients diagnosed with BNS between 2014 and 2021 within the Polish Lymphoma Research Group network. The primary objectives were to assess the overall survival (OS) and mortality from BNS, while secondary objectives included examining the clinical presentation, treatment efficacy, and progression-free survival (PFS).

Diagnosis of BNS was based on established guidelines, requiring either a biopsy of CNS lesions showing lymphoplasmacytic lymphoma (LPL) or detection of LPL cells in cerebrospinal fluid (CSF) with evidence of clonality. Clinically diagnosed BNS was also accepted if patients had suggestive symptoms, abnormal CSF tests, and no histopathological confirmation.

Treatment response was assessed using standardized categories (complete remission, partial response, non-response, relapse). Statistical analysis involved Kaplan-Meier estimators and log-rank tests for survival outcomes, cumulative incidence estimators and Gray's test for competing risks, and Cox proportional hazards regression for identifying prognostic factors.

Datasets

The study utilized data from 11 patients diagnosed with Bing-Neel Syndrome across five Polish centers between 2014 and 2021. This represents a newly compiled dataset for BNS within the Polish population.

Key Insights and Ideas

  • Rarity and Diagnostic Challenge: BNS is exceptionally rare, even within the WM population, making its diagnosis difficult and often delayed. This study underscores the need for increased physician awareness.
  • Diverse Presentation: BNS symptoms are highly variable, ranging from neurological deficits like headaches and gait disorders to cognitive impairment, making it hard to pinpoint.
  • CNS Penetration is Key: Treatments used for BNS primarily focused on agents that can cross the blood-brain barrier, reflecting the CNS-centric nature of the disease.
  • Poor Prognosis: Despite treatment, BNS is associated with a dismal outcome, with a significant proportion of patients succumbing to the disease itself.
  • Prognostic Indicators: Poor performance status (ECOG) and low hemoglobin levels were identified as significant factors correlating with shorter progression-free survival, offering potential targets for risk stratification.

Key Results

  • Patient Cohort: Eleven patients with BNS were identified, with a median age of 61 years at diagnosis.
  • Timing of Diagnosis: The median time from WM diagnosis to BNS diagnosis was 3.5 years, though 27% of patients had simultaneous or near-simultaneous diagnoses.
  • Treatment Response: A cumulative objective response rate of 73% was observed across various treatment regimens. Ibrutinib was used as a first-line treatment in 18% of patients.
  • Survival Outcomes: With a median follow-up of 20 months, the 36-month estimates were: overall survival (OS) at 47%, progression-free survival (PFS) at 33%, and cumulative incidence of BNS-associated death at 41%.
  • Prognostic Factors: Performance status according to ECOG (HR = 7.79) and hemoglobin concentration below 11 g/dL were significantly correlated with PFS.

Limitations and Future Work

The authors acknowledge the significant limitations of this study, primarily its retrospective nature and the very small sample size (n=11). The rarity of BNS inherently limits the ability to gather large patient cohorts, even with multi-national efforts.

Future work should focus on:

  • Increasing Awareness: Continued efforts to educate physicians about BNS are crucial for earlier diagnosis and improved management.
  • Developing Treatment Guidelines: The lack of established treatment guidelines for BNS remains a significant challenge. Further research is needed to identify more effective therapeutic strategies.
  • Investigating Novel Therapies: Given the poor outcomes, exploring novel and more efficacious treatments, potentially including sequential monitoring of biomarkers like MYD88 L265P in CSF, is warranted.
  • Larger Collaborative Studies: Future research should aim for larger, multi-national collaborative studies to overcome the limitations of small sample sizes and provide more robust data on BNS.

Summary updated

Abstract

Bing-Neel syndrome (BNS) is a rare presentation of Waldenström macroglobulinemia (WM). BNS is a consequence of the central nervous system (CNS) involvement by lymphoplasmacytic lymphoma (LPL) and, rarely, the peripheral nervous system. The data on BNS are extremely scarce. Therefore, we performed a multicenter retrospective analysis of BNS patients diagnosed and treated in centers aligned with the Polish Lymphoma Research Group. The analysis covers the years 2014-2021. Eleven patients were included, 55% females and the median age at BNS diagnosis was 61 years. The median time from WM to BNS was 3.5 years; 27% of patients did have a diagnosis of WM and BNS made simultaneously or within 30 days from each other. Isolated parenchymal involvement was the least frequent (20%). Patients were treated with different regimens, mostly able to cross the blood-brain barrier, including 18% treated with ibrutinib first line. The cumulative objective response to treatment was 73%. With the median follow-up of 20 months (95% CI, 2-32), the 36-month estimates were: overall survival (OS) 47%, progression-free survival (PFS) 33%, and cumulative incidence of BNS-associated death 41%. The performance status according to ECOG was significant for PFS (HR = 7.79) and the hemoglobin concentration below 11 g/dL was correlated with PFS. To conclude, BNS is a very rare manifestation of WM. It is associated with a poor outcome with most patients succumbing to BNS.
BibTeX
@article{drozdsokoowska2022bing,
  author = {Joanna Drozd‐Sokołowska and Anna Waszczuk‐Gajda and Magdalena Witkowska and Elżbieta Sienkiewicz and Anna Kopińska and Agnieszka Kołkowska‐Leśniak and Joanna Barankiewicz and Monika Długosz‐Danecka and Piotr Smolewski and Grzegorz Helbig and Ewa Lech‐Marańda and Wojciech Jurczak and Przemysław Biecek and Sebastian Giebel and W Wiktor-Jędrzejczak and Grzegorz Basak},
  title = {{Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia—A Multicenter Report by the Polish Lymphoma Research Group}},
  journal = {Journal of Clinical Medicine},
  year = {2022},
  doi = {10.3390/jcm11154447},
}
Figure